38th week of 2020 patent applcation highlights part 9 |
Patent application number | Title | Published |
20200289424 | PHARMACEUTICAL COMPOSITIONS COMPRISING DELAYED RELEASE GELLING AGENT COMPOSITIONS - Disclosed herein are immediate release solid oral dosage forms, their methods of preparation and use. The immediate release solid oral dosage form may comprise an active agent composition in an immediate release form, such as an opioid analgesic composition and a gelling agent composition in a delayed release form. | 2020-09-17 |
20200289425 | CARBON DOT LIPOSOMES AND USES THEREOF - Disclosed herein are drug-containing vesicles, each of which includes a carbon dot liposome (C-dot liposome) formed by a plurality of Janus particles, which are self-assembled into the C-dot liposome; and a drug encapsulated within the C-dot liposome. Also disclosed herein is a method of producing the drug-containing vesicles. The method includes, mixing a plurality of Janus particles with a drug solution (e.g., an anti-cancer drug solution) to form a mixed solution; and producing the drug-containing vesicles either by a film-hydration method or an injection method. In the film-hydration method, the mixed solution is condensed until a film-like structure is formed; and sonicating the film-like structure in a salt solution to produce the drug-containing vesicle. In the injection method, the mixed solution is rapidly injected into a salt solution to produce the drug-containing vesicle. Also encompasses in the present disclosure are methods for treating a subject afflicted with a cancer. In some embodiments, the method includes administering an effective amount of the drug-containing vesicles to the subject to suppress the growth of the cancer. In other embodiments, the method includes administering an effective amount of C-dot liposome to the subject; and irradiating the subject with a first and a second wavelength of 350-400 nm and 480-550 nm. | 2020-09-17 |
20200289426 | Transdermal Therapeutic System for Administering an Active Substance - The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, said system being suitable for an application period of at least three days, comprising the layers arranged in the following order with respect to each other:
| 2020-09-17 |
20200289427 | FORMULATION AND METHOD FOR SUPPORTING RETINAL HEALTH THEREBY REDUCING THE RISK OF AGE-RELATED MACULAR DEGENERATION (AMD) - A formulation and method for comprehensively supporting retinal health and thereby preventing, reducing the risk of, and/or slowing the progression of Age-Related Macular Degeneration (AMD) are disclosed. The formulation includes optimal daily dosages of vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin. | 2020-09-17 |
20200289428 | METHODS OF PROTECTING THE EYE HEALTH OF CHILDREN EXPOSED TO BLUE AND WHITE LIGHT - The present invention relates generally to a method of reducing the impact on visual performance resulting from exposure to harmful light rays in children through supplementation with lutein and/or zeaxanthin, in particular protecting the eye from damage created due to exposure to blue light and/or white light. | 2020-09-17 |
20200289429 | APPLICATION OF TOTAROL AND PHARMACEUTICAL COMPOSITION CONTAINING TOTAROL - The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and prevention of relapses of such inflammations. The invention includes also a pharmaceutical composition for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment and for prophylaxis and prevention of relapses of such inflammations, the composition containing from 75 to 95 parts by wt. of a cellulose derivative, from 0.5 to 5 parts by wt. of lactic acid, from 0.5 to 5 parts by wt. of a basic polymer, wherein the stoichiometric ratio of lactic acid to the basic polymer is comprised in the range of 1:1 to 8:1, and comprising totarol in an amount of 0.001 to 5 parts by wt. as the active substance. | 2020-09-17 |
20200289430 | Antibacterial Treatments Using Cannabinoids - A method for the treatment or prevention of a topical infection by a bacteria of the genus | 2020-09-17 |
20200289431 | COMBINATION OF CANNABIDIOL AND NSAIDS FOR THE TREATMENT OF SCIATICA AND OTHER NERVE PAIN - Compositions comprising Cannabidiol in combination with non-steroidal anti-inflammatory drugs (NSAIDs) are provided for treating conditions such as sciatica and other nerve pain. | 2020-09-17 |
20200289432 | CONTINUOUS LOCAL SLOW-RELEASE OF THERAPEUTICS FOR HEAD AND NECK PROBLEMS AND UPPER AERODIGESTIVE DISORDERS - The invention features formulations for the local delivery of therapeutically effective doses of curcumin to treat head and neck disorders and upper aerodigestive disorders. Also disclosed are use of the formulations for delivery of other phytochemicals, or the combination of phytochemicals for the treatment of said disorders. Furthermore, these formulations can be used to deliver the recommended daily allowance of vitamins and/or minerals to children or adults. | 2020-09-17 |
20200289433 | ASTAXANTHIN COMPOUND COMPOSITION AND THE METHOD THEREOF - The invention relates to an astaxanthin compound composition, the preparation system and the method of preparing the astaxanthin compound composition. The astaxanthin compound composition comprises | 2020-09-17 |
20200289434 | RAPIDLY IMPROVING ENDOTHELIAL FUNCTION, REDUCING ARTERIAL STIFFNESS AND REVERSING CALCIFICATION OF BLOOD VESSELS BY ADMINISTERING VITAMIN K - A method for rapidly improving cardiovascular function, reducing arterial stiffness and reversing calcification of a blood vessel in a mammal comprising administering to the mammal an effective amount of vitamin K for a period of 2 weeks to less than 6 months. Also a method for increasing endothelial nitric oxide production in mammals comprising administering to the mammal an effective amount of vitamin K for a period of 2 to 8 weeks. The vitamin K can be administered together with additional substances such as vitamin D. | 2020-09-17 |
20200289435 | MATERIALS AND METHODS FOR CONTROLLING INFECTIONS - The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible. | 2020-09-17 |
20200289436 | NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES - The present invention relates to novel methods of using a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, | 2020-09-17 |
20200289437 | Compositions for Modulating Cancer Stem Cells and Uses Therefor - Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence. | 2020-09-17 |
20200289438 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA - In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42. | 2020-09-17 |
20200289439 | Process of Manufacturing a Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation - A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient is provided. The oxidation susceptible active pharmaceutical ingredient is mixed with excipients and deoxygenated water to prepare a non-sterile drug solution. The non-sterile drug solution is filled into a moist heat sterilizable flexible infusion bag. The flexible infusion bag with the non-sterile drug solution is terminally moist heat sterilized at a preset air overpressure between about 0.2 bar to about 1.2 bar to obtain a parenteral drug product. The highest degradation product in the parenteral drug product is less than 0.5% by weight of a labeled amount of the oxidation susceptible active pharmaceutical ingredient in the parenteral drug product. | 2020-09-17 |
20200289440 | Use of Formin Agonists in Overcoming Brain Tumor Radio- and Chemo-resistance by Targeting Tumor Microtubes - Compositions and methods for inhibiting brain tumor proliferation, or for inhibiting or halting TM formation, invasion, and/or proliferation, or for rendering brain tumor cells sensitive to chemotherapy or radiation, or for treating a brain tumor, or for inducing cell death, involving mDia agonists such as IMM01 and IMM02, are described. | 2020-09-17 |
20200289441 | METHODS FOR PROMOTING HAIR GROWTH USING VALPROIC ACID - The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation; and administration of a pharmaceutical composition (e.g., a pharmaceutical composition comprising valproic acid or a pharmaceutically acceptable salt thereof). | 2020-09-17 |
20200289442 | SUPPORTING IMMUNOMODULATORY AGENT - The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C | 2020-09-17 |
20200289443 | Method of Citric Acid as a Biochemical Enhancer - Methods for the metabolic manipulation with citric acid prolonging and amplifying the effects of pharmacological therapies including neurotoxins and citrate through taxis and its effects on acetylcholine, immunological factors, calcium and the localized depletion of o2. Citric acid provides for longer lasting medical grade neurotoxin results related to paralysis by its effects, dose related, on acetylcholine and through commutative irritating responses in tissues. Outcomes are through acetylcholine amplification and immunoreactivity, and a lack thereof, providing longer lasting results through acetylcholine biochemical taxis. Pertinent to these effects, neurotoxins such as | 2020-09-17 |
20200289444 | Methods and Compositions for Supporting Renal Health - Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions. | 2020-09-17 |
20200289445 | NOVEL MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS - The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza vims infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone. | 2020-09-17 |
20200289446 | CYSTEINE COMPOSITION AND INJECTION - Cysteine compositions comprising less than about 400 μg/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 μg/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof. | 2020-09-17 |
20200289447 | CYSTEINE COMPOSITION AND INJECTION - Cysteine compositions comprising less than about 400 μg/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 μg/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof. | 2020-09-17 |
20200289448 | CYSTEINE COMPOSITION AND INJECTION - Cysteine compositions comprising less than about 400 μg/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 μg/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof. | 2020-09-17 |
20200289449 | D-Serine Inhibit Neuroinflammation Due To A Brain Injury - D-serine is effective for inhibiting neuron loss due to an immune response by glial cells to a brain injury. An example of a method includes artificially administering a composition including D-serine to brain cells after an injury thereto, the composition including an amount of D-serine effective to inhibit death of neurons. | 2020-09-17 |
20200289450 | METHODS OF REDUCING OR PREVENTING OXIDATIVE MODIFICATION OF MEMBRANE POLYUNSATURATED FATTY ACIDS - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing membrane cholesterol domain formation in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2020-09-17 |
20200289451 | METHODS FOR TREATING THROMBOCYTOPENIA - The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor. | 2020-09-17 |
20200289452 | ORAL COMPOSITION FOR THE TREATMENT OF CANKER SORES - A composition, and method for using the same, for treating a canker sore includes 10-30% of an ester local anesthetic, 0.5-2% of a corticosteroid, and a carrier for the ester local anesthetic and the corticosteroid. The carrier is formulated as a paste so as to be applied topically to the canker sore to deliver the ester local anesthetic and the corticosteroid simultaneously to the canker sore. | 2020-09-17 |
20200289453 | Pharmaceutical Combinations and Methods for the Treatment of Diabetes and Associated Disorders - The invention relates to pharmaceutical compositions comprising combinations of flavonoids that may be used to treat and/or prevent diabetes and associated diseases, conditions and/or disorders. The invention also relates to methods of treating diabetes and associated diseases, conditions and/or disorders using the pharmaceutical compositions. | 2020-09-17 |
20200289454 | USE OF BENZOFURAN LIGNANS TO INDUCE IL-25 EXPRESSION AND SUPPRESS MAMMARY TUMOR METASTASIS - A method for suppressing tumor metastasis, in which an effective amount of a compound of formula (I) is administered to a subject in need thereof. Also disclosed is a method of treating cancer, in which an effective amount of a chemotherapy agent and an effective amount of a compound of formula (I) is administered to a subject in need thereof. Further disclosed are pharmaceutical compositions for suppressing tumor metastasis and for treating cancer, each of the compositions containing a compound of formula (I). | 2020-09-17 |
20200289455 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE - Pharmaceutical compositions are described, the compositions comprising therapeutically effective quantities of compounds (such as mycophenolic acid or cyclosporine) that are capable of treating, preventing, and/or or alleviating an ocular surface disease. Methods for fabricating the compositions and using them are also described. | 2020-09-17 |
20200289456 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE - Compositions and methods are provided for improving the treatment of tumors by inhibiting cytochrome P450 enzymes (“CYPs”) expressed by tumors. Inhibition of tumor-expressed CYPs provides improved dosing of anti-tumor drugs, inhibits development of drug resistance by tumors and provides improved patient outcomes. | 2020-09-17 |
20200289457 | COMPOUND FOR THE MANAGEMENT OF FELINE DIABETES - Provided herein are methods of managing feline diabetes, said methods include administering to a feline in need thereof a total daily dosage of about 5 to 50 mg of Compound 1, having the formula: | 2020-09-17 |
20200289458 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN - Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate. | 2020-09-17 |
20200289459 | LIQUID DOSAGE FORMS, METHODS OF MAKING AND USE - and cannabis derived formulations, methods of making and methods of using the formulation in oral dosage forms, preferably in beverage forms, are disclosed herein. | 2020-09-17 |
20200289460 | CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF - Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7. | 2020-09-17 |
20200289461 | PREVENTION AND TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN - A method of preventing and/or treating disease in which reactive oxygen species (or ROSs) of mitochondrial origin are involved. The method involves use of an inhibitor of mitochondrial ROS production, in particular, of anethole trithione, for the prevention and/or treatment of benign prostatic hyperplasia. | 2020-09-17 |
20200289462 | SANFETRINEM OR A SALT OR ESTER THEREOF FOR USE IN TREATING MYCOBACTERIAL INFECTION - The present invention relates to | 2020-09-17 |
20200289463 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS - The present application relates to compounds of formula (I), wherein A, R, R | 2020-09-17 |
20200289464 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS - The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy. | 2020-09-17 |
20200289465 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS - The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus. | 2020-09-17 |
20200289466 | METHODS AND USES OF NAMPT ACTIVATORS FOR TREATMENT OF DIABETES, CARDIOVASCULAR DISEASES, AND SYMPTOMS THEREOF - Described herein are methods and uses of Nampt activators for treatment of cardiovascular diseases and disorders, and/or diabetes, symptoms thereof, and complications associated with diabetes. | 2020-09-17 |
20200289467 | FORMULATIONS COMPRISING TRIPTAN COMPOUNDS - The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T | 2020-09-17 |
20200289468 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation. | 2020-09-17 |
20200289469 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. | 2020-09-17 |
20200289470 | SECNIDAZOLE FOR USE IN THE TREATMENT OF TRICHOMONIASIS - Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of trichomoniasis in a subject in need thereof. | 2020-09-17 |
20200289471 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE - The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections. | 2020-09-17 |
20200289472 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS - The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1. | 2020-09-17 |
20200289473 | METHODS OF TREATING NEURODEGENERATION - The present invention provides methods and compositions for treating a CNS disease, disorder or injury, (e.g., a CNS demyelinating disease). The present invention provides methods and compositions for preserving or protecting neuroaxonal activity in a subject, preferably a mammalian subject (e.g., a human) by administering one or more compositions that inhibit the activity of γ-glutamyl transpeptidase in the human subject. | 2020-09-17 |
20200289474 | METHODS OF TREATING PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC - Methods of treating diabetic neuropathic pain and post-surgical pain are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat diabetic neuropathy arising from any type of nerve damage, and can also be used to treat post-surgical pain arising from any surgical procedure without the side effects associated with widely used analgesics such as opioids. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets. | 2020-09-17 |
20200289475 | RILUZOLE PRODRUGS AND THEIR USE - Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. | 2020-09-17 |
20200289476 | LIQUID FORMULATIONS OF RILUZOLE FOR ORAL AND INTRAVENOUS USE - Embodiments of the present disclosure pertain to compositions that include a liquid formulation comprising a molecule selected from the group consisting of riluzole, a derivative of riluzole, an analog of riluzole, a pharmaceutical equivalent of riluzole, a benzothiazole-based molecule, combinations thereof, and salts thereof. The liquid formulations may also include a solubilizing agent. Additional embodiments of the present disclosure pertain to methods of treating a condition or disease in a subject by administering to the subject a composition of the present disclosure. The condition or disease to be treated may include spinal cord injury, and the administration may occur by parenteral administration. In some embodiments, the administered molecule may have an absorption half-life of less than 1.5 hours, an elimination half-life of more than 10 hours, and a bioavailability of more than 65%. Additional embodiments of the present disclosure pertain to methods of making the compositions. | 2020-09-17 |
20200289477 | CONJOINT THERAPIES FOR IMMUNOMODULATION - The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2. | 2020-09-17 |
20200289478 | SOLID DISPERSIONS COMPRISING TACROLIMUS - A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability. | 2020-09-17 |
20200289479 | STABILIZED TRANSDERMAL DELIVERY SYSTEM - The present invention concerns a method for the production of a transdermal delivery system (TDS) comprising at least one active ingredient, wherein the method comprises temperature-conditioning. Furthermore, the present invention concerns a TDS which can be produced by means of the method in accordance with the invention, as well as the use of the TDS in accordance with the invention. | 2020-09-17 |
20200289480 | PERGOLIDE FOR USE IN THE TREATMENT OF EYE DISEASES ASSOCIATED WITH AN ELEVATED LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND PHARMACEUTICAL COMPOSITION CONTAINING PERGOLIDE - The object of the invention is pergolide for use in the treatment of eye diseases associated with an elevated level of vascular endothelial growth factor (VEGF) and a pharmaceutical composition for use in the treatment of eye diseases associated with an elevated level of vascular endothelial growth factor (VEGF), characterised in that it contains pergolide and a pharmaceutically acceptable carrier. | 2020-09-17 |
20200289481 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION - The present invention provides a composition for improving the sustained-release ability of N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof. More specifically, the present invention provides a composition for topical administration comprising N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof and a polycation polymer. | 2020-09-17 |
20200289482 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - Described are methods of treating cystic kidney disease. Also disclosed are methods of reducing the size and/or number of cysts in autosomal dominant polycystic kidney disease. | 2020-09-17 |
20200289483 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND - Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof. | 2020-09-17 |
20200289484 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation. | 2020-09-17 |
20200289485 | A MALEATE SALT OF THE FREE BASE OF N-[5-(AMINOSULFONYL)-4-METHYL-1.3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINY- L)-PHENYL]-ACETAMIDE, PHARMACEUTICAL FORMULATIONS, METHODS OF MANUFACTURE AND USES THEREOF FOR THE TREATMENT OF HERPES VIRUSES - The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particulary infections caused by HSV-1 and HSV-2. | 2020-09-17 |
20200289486 | Enantiomers Of Substituted Thiazoles As Antiviral Compounds - The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments. | 2020-09-17 |
20200289487 | ANIMAL TREATMENTS - Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal. | 2020-09-17 |
20200289488 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF - A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. | 2020-09-17 |
20200289489 | COMBINATION FOR TREATING PAIN - The invention provides compounds, compositions, and methods for treating pain. | 2020-09-17 |
20200289490 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation. | 2020-09-17 |
20200289491 | Novel compounds for use in treating depression and migraine - The invention relates to amide-derivatives of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid for use in a treatment for preventing or suppressing symptoms associated with mood disorders, headaches and migraine. The compounds of the invention can be used to treat any subject suffering from a mood disorder, headaches and/or migraine but can specifically be used to treat a mood disorder, headaches and/or migraine in patients suffering from a mitochondrial disease. | 2020-09-17 |
20200289492 | DRUG FOR TREATING COCAINE ADDICTION OR PREVENTING RECURRENCE OF SAME - The present invention provides a drug for treating cocaine addiction or preventing the relapse of the same. Specifically, the present invention provides a drug for treating cocaine addiction or preventing the relapse of the same containing (R)-2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide or a pharmaceutically acceptable salt thereof. | 2020-09-17 |
20200289493 | COMBINATION THERAPIES FOR TREATING CANCER - The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling. | 2020-09-17 |
20200289494 | NIRAPARIB FORMULATIONS - The present invention relates to pharmaceutical tablet compositions comprising the compound niraparib as an active pharmaceutical ingredient, suitable for oral administration as well as to methods for their preparation. Also described herein are tablet compositions containing niraparib formed by the disclosed methods, and therapeutic uses of such tablet compositions for treating various disorders and conditions. | 2020-09-17 |
20200289495 | METHODS OF INHIBITING ENDOTHELIN B RECEPTOR EXPRESSING TUMOR METASTASES - The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain. | 2020-09-17 |
20200289496 | PYRIDYLPYRIDONE COMPOUNDS - The invention provides novel pyridylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R | 2020-09-17 |
20200289497 | ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS - The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders. | 2020-09-17 |
20200289499 | PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA - The present disclosure is related to methods of treating agitation and/or aggression and/or associated symptoms in subjects with dementia, including, dementia associated with Alzheimer's disease. The method includes administering to a subject in need thereof a dextromethorphan compound, or a pharmaceutically acceptable salt thereof, in combination with quinidine, or a pharmaceutically acceptable salt thereof. The disclosure in certain aspects is also related to compositions that are used for treating agitation and/or aggression and/or associated symptoms in subjects suffering from Alzheimer's disease. | 2020-09-17 |
20200289500 | METHODS OF TREATING ACUTE OR CHRONIC PAIN - The invention provides methods for treating chronic and acute pain. For example, the invention provides methods of treating neuropathic and inflammatory pain. | 2020-09-17 |
20200289502 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY - Described herein are methods for using compounds that activate pyruvate kinase. | 2020-09-17 |
20200289503 | METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION - Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof. | 2020-09-17 |
20200289504 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS - The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates. | 2020-09-17 |
20200289505 | PHARMACEUTICAL COMPOSITION FOR CANCER IMMUNOTHERAPY AND/OR IMMUNOLOGICAL ACTIVATION CONTAINING DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT - [Problem] A compound useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for cancer immunotherapy, and/or a pharmaceutical composition for immunological activation is provided. | 2020-09-17 |
20200289506 | COMBINATION OF A BTK INHIBITOR AND AN INHIBITOR OR CDK9 TO TREAT CANCER - The present invention relates to combination of a BTK inhibitor and an inhibitor of CDK9 for use in the treatment of cancer in a subject. The BTK inhibitor can be acalabrutinib, ibrutinib, or ONO/GS-4059; and the inhibitor of CDK9 can be AZD4573, BAY-1251152, BAY-1143572, CYC065, alvocidib, AT7519, voruciclib, roniciclib, or dinaciclib. | 2020-09-17 |
20200289507 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS - The present invention relates to derivatives of formula (I) | 2020-09-17 |
20200289508 | NOVEL PYRIMIDINYL-DIAZOSPIRO COMPOUNDS - The invention relates to Spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation. | 2020-09-17 |
20200289509 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS - The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R | 2020-09-17 |
20200289510 | METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION AND ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND DAILY DOSING - There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose. | 2020-09-17 |
20200289511 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DIABETIC NEPHROPAPHY INCLUDING ADENOSINE DERIVATIVE - A pharmaceutical composition for preventing or treating diabetic nephropathy is provided. According to the present invention, a pharmaceutical composition for preventing or treating diabetic nephropathy comprises an adenosine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. | 2020-09-17 |
20200289512 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF - The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like. | 2020-09-17 |
20200289513 | Treating Cancer with Drug Combinations - Embodiments of the disclosure find application in the field of cancer therapy. Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. | 2020-09-17 |
20200289514 | Novel Pyrazolo Pyrimidine Derivatives - The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity. | 2020-09-17 |
20200289515 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS - Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors. | 2020-09-17 |
20200289516 | ANNULATED GLYCOSIDASE INHIBITORS - Compounds of formula (I), wherein A, R, W | 2020-09-17 |
20200289517 | Methods for Treating Lymphoid Malignancies - The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens. | 2020-09-17 |
20200289518 | METHOD FOR TREATING BRAIN OR NERVE INJURY - The invention provides a method for treating brain or nerve injury. | 2020-09-17 |
20200289519 | NOVEL USES - The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A | 2020-09-17 |
20200289520 | COMPOSITION AND METHOD FOR TREATING PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA - The present invention relates to the use of a dual selective PI3K delta and gamma protein kinase inhibitor, such as (S)-2-(1-((9H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (Compound (A), also known as tenalisib) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing such an inhibitor for the treatment of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). 34 139095.00100/115268675v.1 | 2020-09-17 |
20200289521 | USE OF VITAMIN K IN COMBINATION WITH ANTICOAGULANTS - A method of treating or preventing a condition characterized by unacceptable blood clotting and/or an increased risk thereof, the method including administering to a subject in need thereof a combination of vitamin K2 and at least one anticoagulant, the at least one anticoagulant having a first anticoagulant configured to inhibit free Factor Xa and/or Factor Xa bound in a prothrombinase complex of the subject. | 2020-09-17 |
20200289522 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR - A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having an influenza virus infection and at least one complication risk factor. Generally, the amount is effective such that a reduction in a time to improvement of at leat one symptom of an influenza virus infection is statistically significant as compared to that of a non-treated subject. | 2020-09-17 |
20200289523 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION - The present invention relates to fixed dose pharmaceutical compositions comprising the active substances Candesartan cilexetil, Amiodipine and Hydrochlorothiazide for the treatment of hypertension. | 2020-09-17 |
20200289524 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-09-17 |
20200289525 | Methods of Increasing Microbial Diversity of a Skin Microbiota - Materials and methods for selectively increasing the diversity of the skin microbiota of a subject with an amenable skin condition are provided in disclosing methods for using compositions comprising a zinc compound, a biocompatible surfactant, and a lipid. Amenable skin conditions include healthy skin and skin exhibiting atopic dermatitis (with or without lesions), skin dysbiosis and/or acne. | 2020-09-17 |